Newscope Capital Corporation: RichTV in Discussion With the CEO Fabio Chianelli

The existence of the internet has made it a lot easier for people to get all kinds of information imaginable with regard to the stock market. YouTube has become one of the more popular platforms for such information and many channels have cropped up which provide reliable information that will be valued by investors.

One such channel is RichTV Live, which focuses on providing analysis of the latest news from the markets and also analyses individual stocks from across a wide range of sectors. In its latest video, RichTV showcased the company Capital Corporation (CNSX:PHRM) (OTCQB:PHRRF) and spoke at length about the company’s business with Fabio Chianelli, the CEO of the Company.

Enter Your E-mail Address To Subscribe

* indicates required

Key Discussions

In this regard, it is necessary to point out that Newscope has now branched into a potentially fast-growing sector through its fully owned subsidiary PharmaTher Inc. PharmaTher is currently involved in the research and development with relation to psychedelics based medicines.

Recently, PharmaTher made a major announcement as well which could prove to be a major boost to its business in the long run. The company announced that it signed an Exclusive Worldwide Patent and Knowhow Licensing Agreement with The Queen’s University of Belfast. According to the terms of the agreement, the company is going to use the hydrogel-forming microneedle delivery technology developed by the university in its own initiatives.

On the other hand, the stock is doing quite well as well and that was how the discussion was started off in the live interview yesterday. The founder stated that he established the company PharmaTher with a specific focus on treating mental health issues, pain disorders, and other forms of neurological disorders. In order to accomplish that, the founders decided to take the route of psychedelics based medicines. It is necessary to point out that this particular space has grown by leaps and bounds in recent times.

Many companies have sprung up which are now involved in conducting enormous amounts of research in order to come up with viable products that could lead to the long term well being of people. In this regard, potential investors would be interested to note the comment from the founder with regards to the fact that PharmaTher currently boasts of a total of as many as 19 patents and patent applications.

Featured image: Pixabay

Please See Disclaimer

If You Liked This Article Click To Share

Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of or its officers. The author is wholly responsible for the validity of all statements. was not involved in any aspect of the article preparation. The author was not paid by Bitrex Inc for this article. The author did not pay to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. does not render general or specific investment advice. Any information on should not be considered a recommendation to buy or sell any security. does not endorse or recommend the business, products, services or securities of any company mentioned on

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.